P

Assignee

JOLLA PHARMA

US32 patents

Top patents by PatentIndex Score

US5552391ASep 3, 1996

Chemically-defined non-polymeric valency platform molecules and conjugates thereof

JOLLA PHARMA160 citations98
US5817752AOct 6, 1998

Cyclic polypeptides comprising a thioether linkage and methods for their preparation

JOLLA PHARMA65 citations96
US5276013AJan 4, 1994

Conjugates of biologically stable polyfunctional molecules and polynucleotides for treating systemic lupus erythematosus

JOLLA PHARMA59 citations96
US6207160B1Mar 27, 2001

aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies

JOLLA PHARMA70 citations95
US5726329AMar 10, 1998

Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides

JOLLA PHARMA53 citations95
US5606047AFeb 25, 1997

Chemically-defined non-polymeric valency platform molecules and conjugates thereof

JOLLA PHARMA65 citations95
US6060056AMay 9, 2000

Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule

JOLLA PHARMA58 citations94
US6031073AFeb 29, 2000

Cyclic polypeptides comprising a thioether linkage and methods for their preparation

JOLLA PHARMA33 citations93
US5268454ADec 7, 1993

Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier

JOLLA PHARMA42 citations93
US7351855B2Apr 1, 2008

Chemically defined non-polymeric valency platform molecules and conjugates thereof

JOLLA PHARMA24 citations92
US6951939B2Oct 4, 2005

Multivalent platform molecules comprising high molecular weight polyethylene oxide

JOLLA PHARMA18 citations92
US5874552AFeb 23, 1999

Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides

JOLLA PHARMA29 citations92
US5633395AMay 27, 1997

Chemically-defined non-polymeric valency platform molecules and conjugates thereof

JOLLA PHARMA33 citations92
US5162515ANov 10, 1992

Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus

JOLLA PHARMA40 citations92
US6410775B1Jun 25, 2002

APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

JOLLA PHARMA18 citations91
US6399578B1Jun 4, 2002

Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same

JOLLA PHARMA21 citations91
US5874409AFeb 23, 1999

APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies

JOLLA PHARMA42 citations90
US6858210B1Feb 22, 2005

Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same

JOLLA PHARMA33 citations88
US6458953B1Oct 1, 2002

Valency platform molecules comprising carbamate linkages

JOLLA PHARMA16 citations84
US6166198ADec 26, 2000

Methods for oligonucleotide synthesis

JOLLA PHARMA12 citations73
US5017648AMay 21, 1991

D-GL conjugate therapy

JOLLA PHARMA7 citations73
US4950469AAug 21, 1990

D-GL conjugate therapy

JOLLA PHARMA12 citations73
US4950713AAug 21, 1990

Conjugates of D-glutamic acid: D-lysine copolymer and certain biochemicals

JOLLA PHARMA9 citations73
US7163683B2Jan 16, 2007

Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule

JOLLA PHARMA9 citations71
US7138244B2Nov 21, 2006

Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule

JOLLA PHARMA7 citations70
US7081242B1Jul 25, 2006

Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

JOLLA PHARMA9 citations63
US8877263B2Nov 4, 2014

Modified pectins, compositions and methods related thereto

JOLLA PHARMA2 citations61
US8722111B2May 13, 2014

Modified pectins, compositions and methods related thereto

JOLLA PHARMA2 citations61
US8658224B2Feb 25, 2014

Modified pectins, compositions and methods related thereto

JOLLA PHARMA1 citations61
US7208156B2Apr 24, 2007

Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule

JOLLA PHARMA2 citations60
US7115581B2Oct 3, 2006

Chemically-defined non-polymeric valency platform molecules and conjugates thereof

JOLLA PHARMA1 citations52
US9181354B2Nov 10, 2015

Modified pectins, compositions and methods related thereto

JOLLA PHARMA0 citations51